MUC1-C ACTIVATES THE TAK1 INFLAMMATORY PATHWAY IN COLON CANCER

[1]  J. Ninomiya-Tsuji,et al.  TAK1 control of cell death , 2014, Cell Death and Differentiation.

[2]  H. Ngan,et al.  Elevated TAK1 augments tumor growth and metastatic capacities of ovarian cancer cells through activation of NF-κB signaling , 2014, Oncotarget.

[3]  D. Kufe,et al.  MUC1-C oncoprotein activates the ZEB1/miR-200c regulatory loop and epithelial–mesenchymal transition , 2014, Oncogene.

[4]  D. Kufe,et al.  MUC1-C Oncoprotein Activates ERK→C/EBPβ Signaling and Induction of Aldehyde Dehydrogenase 1A1 in Breast Cancer Cells* , 2013, The Journal of Biological Chemistry.

[5]  J. Hurley,et al.  The molecular genetics of colorectal cancer , 2013, Frontline Gastroenterology.

[6]  Helen Y Wang,et al.  Cell type-specific function of TAK1 in innate immune signaling. , 2013, Trends in immunology.

[7]  D. Kufe.  MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches , 2013, Oncogene.

[8]  Travis J Cohoon,et al.  Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. , 2013, Cancer cell.

[9]  H. Sakurai.  Targeting of TAK1 in inflammatory disorders and cancer. , 2012, Trends in pharmacological sciences.

[10]  M. Hoenerhoff,et al.  Inhibition of transforming growth factor-β-activated kinase-1 blocks cancer cell adhesion, invasion, and metastasis , 2012, British Journal of Cancer.

[11]  Min Yu,et al.  TAK1 Inhibition Promotes Apoptosis in KRAS-Dependent Colon Cancers , 2012, Cell.

[12]  J. Ninomiya-Tsuji,et al.  Epithelial transforming growth factor β-activated kinase 1 (TAK1) is activated through two independent mechanisms and regulates reactive oxygen species , 2012, Proceedings of the National Academy of Sciences.

[13]  D. Kufe,et al.  MUC1-C Oncoprotein Induces TCF7L2 Transcription Factor Activation and Promotes Cyclin D1 Expression in Human Breast Cancer Cells* , 2012, The Journal of Biological Chemistry.

[14]  D. Kufe,et al.  Targeting cysteine-mediated dimerization of the MUC1-C oncoprotein in human cancer cells. , 2011, International journal of oncology.

[15]  D. Kufe,et al.  A monoclonal antibody against the oncogenic mucin 1 cytoplasmic domain. , 2011, Hybridoma.

[16]  S. Lam,et al.  TRAF6 is an amplified oncogene bridging the RAS and NF-κB pathways in human lung cancer. , 2011, The Journal of clinical investigation.

[17]  S. Itzkowitz,et al.  Intestinal inflammation and cancer. , 2011, Gastroenterology.

[18]  G. Shapiro,et al.  Dependence on the MUC1-C Oncoprotein in Non–Small Cell Lung Cancer Cells , 2011, Molecular Cancer Therapeutics.

[19]  D. Kufe,et al.  MUC1-C Oncoprotein Promotes STAT3 Activation in an Autoinductive Regulatory Loop , 2011, Science Signaling.

[20]  A. Velcich,et al.  Importance and regulation of the colonic mucus barrier in a mouse model of colitis. , 2011, American journal of physiology. Gastrointestinal and liver physiology.

[21]  J. Ninomiya-Tsuji,et al.  Ablation of TAK1 upregulates reactive oxygen species and selectively kills tumor cells. , 2010, Cancer research.

[22]  S. Ranganathan,et al.  Aberrant Expression of MUC1 Mucin in Pediatric Inflammatory Bowel Disease , 2010, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

[23]  D. Kufe,et al.  Mucins in cancer: function, prognosis and therapy , 2009, Nature Reviews Cancer.

[24]  S. Akira,et al.  Two Mechanistically and Temporally Distinct NF-κB Activation Pathways in IL-1 Signaling , 2009, Science Signaling.

[25]  D. Kufe,et al.  MUC1-C oncoprotein functions as a direct activator of the nuclear factor-kappaB p65 transcription factor. , 2009, Cancer research.

[26]  R. Weichselbaum,et al.  MUC1-induced transcriptional programs associated with tumorigenesis predict outcome in breast and lung cancer. , 2009, Cancer research.

[27]  M. Karin,et al.  IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. , 2009, Cancer cell.

[28]  Y. Niv,et al.  MUC1 and colorectal cancer pathophysiology considerations. , 2008, World journal of gastroenterology.

[29]  D. Kufe,et al.  MUC1 oncoprotein activates the IκB kinase β complex and constitutive NF-κB signalling , 2007, Nature Cell Biology.

[30]  V. Korolik,et al.  MUC1 cell surface mucin is a critical element of the mucosal barrier to infection. , 2007, The Journal of clinical investigation.

[31]  A. Sepulveda,et al.  Cutting Edge: Transgenic Expression of Human MUC1 in IL-10−/− Mice Accelerates Inflammatory Bowel Disease and Progression to Colon Cancer1 , 2007, The Journal of Immunology.

[32]  J. Scholefield,et al.  The role of MUC1 and MUC3 in the biology and prognosis of colorectal cancer , 2007, World journal of surgical oncology.

[33]  J. Jass,et al.  Prognostic significance of mucins in colorectal cancer with different DNA mismatch-repair status , 2006, Journal of Clinical Pathology.

[34]  C. Cherbut,et al.  MUC Genes Are Differently Expressed During Onset and Maintenance of Inflammation in Dextran Sodium Sulfate-Treated Mice , 2006, Digestive Diseases and Sciences.

[35]  L. Yin,et al.  MUC1 Oncoprotein Blocks Glycogen Synthase Kinase 3β–Mediated Phosphorylation and Degradation of β-Catenin , 2005 .

[36]  Myles A Brown,et al.  Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking. , 2005, Molecular cell.

[37]  Michael Karin,et al.  IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer , 2004, Cell.

[38]  M. Merville,et al.  15-Deoxy-Δ12,14-prostaglandin J2 Inhibits Bay 11-7085-induced Sustained Extracellular Signal-regulated Kinase Phosphorylation and Apoptosis in Human Articular Chondrocytes and Synovial Fibroblasts* , 2004, Journal of Biological Chemistry.

[39]  D. Kufe,et al.  The MUC1 Oncoprotein Activates the Anti-apoptotic Phosphoinositide 3-Kinase/Akt and Bcl-xL Pathways in Rat 3Y1 Fibroblasts* , 2004, Journal of Biological Chemistry.

[40]  J. Rhodes,et al.  Altered glycosylation in inflammatory bowel disease: A possible role in cancer development , 2001, Glycoconjugate Journal.

[41]  T. Irimura,et al.  Expression of MUC1 recognized by monoclonal antibody MY.1E12 is a useful biomarker for tumor aggressiveness of advanced colon carcinoma , 2004, Clinical & Experimental Metastasis.

[42]  R. Bresalier,et al.  Mucins and mucin binding proteins in colorectal cancer , 2004, Cancer and Metastasis Reviews.

[43]  D. Kufe,et al.  Human DF3/MUC1 carcinoma-associated protein functions as an oncogene , 2003, Oncogene.

[44]  R. Surabhi,et al.  TAK1 is Critical for IκB Kinase-mediated Activation of the NF-κB Pathway , 2003 .

[45]  R. Surabhi,et al.  TAK1 is critical for IkappaB kinase-mediated activation of the NF-kappaB pathway. , 2003, Journal of molecular biology.

[46]  A. Hölscher,et al.  Comparative evaluation of the prognostic value of MUC1, MUC2, sialyl‐Lewisa and sialyl‐Lewisx antigens in colorectal adenocarcinoma , 2002, Histopathology.

[47]  Zhijian J. Chen,et al.  TAK1 is a ubiquitin-dependent kinase of MKK and IKK , 2001, Nature.

[48]  M. Hollingsworth,et al.  Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model. , 1998, Cancer research.

[49]  M. Leach,et al.  Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. , 1996, The Journal of clinical investigation.

[50]  J. Rhodes,et al.  Unifying hypothesis for inflammatory bowel disease and associated colon cancer: sticking the pieces together with sugar , 1996, The Lancet.

[51]  D. Ota,et al.  MUC1 mucin expression as a marker of progression and metastasis of human colorectal carcinoma. , 1994, Gastroenterology.